Original Research Article from the North Pacific Surgical Association| Volume 221, ISSUE 6, P1195-1199, June 2021

Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy


      • A 31-gene genetic expression profile (31-GEP) was developed to predict outcome in cutaneous melanoma (CM) patients.
      • Recurrence rates were higher for Class 2 vs Class 1 patients and highest in patients who were Class 2 and SNB positive.
      • Both AJCC stage and GEP class were independently predictive of both RFS and DMF.
      • GEP Class independently predicted relapse in AJCC “low risk” (stages IA-IIA) patients.
      • 31-GEP adds prognostic information in the evaluation of primary CM and should be considered in patents referred for SNB.



      A 31-gene genetic expression profile (31-GEP; Class 1 = low risk, Class 2 = high risk) developed to predict outcome in cutaneous melanoma (CM) has been validated by retrospective, industry-sponsored, or small series.


      Tumor features, sentinel node biopsy (SNB) results, and outcomes were extracted from a prospective database of 383 C M patients who underwent SNB and had a 31-GEP run on their primary tumor. Groups were compared by uni- and multi-variable analysis. Relapse-free and distant metastasis-free survival (RFS, DMFS) were estimated by Kaplan-Meier method.


      Breslow thickness, T stage, and SNB positivity were significantly higher in Class 2 patients. Recurrence rates were higher for Class 2 vs Class 1 patients and highest in patients who were Class 2 and SNB positive. GEP class was predictive of RFS and DMFS and independently predicted relapse in AJCC “low risk” (stages IA-IIA) patients.


      31-GEP adds prognostic information in CM patents undergoing SNB.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ali Z.
        • Yousaf N.
        • Larkin J.
        Melanoma epidemiology, biology and prognosis.
        Eur J Canc. 2013; 11: 81-91
        • Leonardi G.C.
        • Falzone L.
        • Salemi R.
        • et al.
        Cutaneous melanoma: from pathogenesis to therapy (Review).
        Int J Oncol. 2018; 52: 1071-1080
        • Poklepovic A.S.
        • Carvajal R.D.
        Prognostic value of low tumor burden in patients with melanoma.
        Oncology. 2018; 32: e90-e96
        • Gershenwald J.E.
        • Scolyer R.A.
        Melanoma staging: American Joint committee on cancer (AJCC) 8th edition and beyond.
        Ann Surg Oncol. 2018; 25: 2105-2110
        • Siow Z.R.
        • De Boer R.H.
        • Lindeman G.J.
        • et al.
        Spotlight on the utility of the Oncotype DX breast cancer assay.
        Int J Womens Health. 2018; 10: 89-100
        • Gerami P.
        • Cook R.W.
        • Wilkinson J.
        • et al.
        Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma.
        Clin Canc Res. 2015; 21: 175-183
        • Gerami P.
        • Cook R.W.
        • Russell M.C.
        • et al.
        Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy.
        J Am Acad Dermatol. 2015; 72: 780-785
        • Zager J.S.
        • Gastman B.R.
        • Leachman S.
        • et al.
        Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
        BMC Canc. 2018; 18: 130-141
        • Gastman B.R.
        • Gerami P.
        • Kurley S.J.
        • Cook R.W.
        • Leachman S.
        • Vetto J.T.
        Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.
        J Am Acad Dermatol. 2019; 80: 149-157
        • Greenhaw B.N.
        • Zitelli J.A.
        • Brodland D.G.
        • et al.
        Estimation of prognosis in invasive cutaneous melanoma: an independent study of the accuracy of a gene expression profile test.
        Dermatol Surg. 2018; 44: 1494-1500
        • Greenhaw B.N.
        • Covington K.R.
        • Kurley S.J.
        Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients.
        J Am Acad Dermatol. 2020; 83: 745-753
        • Hsueh E.C.
        • DeBloom J.R.
        • Lee J.
        • Sussman J.J.
        • et al.
        Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.
        J Hematol Oncol. 2017; 10: 152-160
        • Keller J.
        • Schwartz T.L.
        • Lizalek J.M.
        Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.
        Cancer Med. 2019; 8: 2205-2212
        • Podlipnik S.
        • Carrera C.
        • Boada A.
        • et al.
        Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. A prospective multicentre cohort study.
        J Eur Acad Dermatol Venereol. 2019; 33: 857-862
        • Han D.
        • Zager J.S.
        • Shyr Y.
        • et al.
        Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.
        J Clin Oncol. 2013; 31: 4387-4393
        • National Comprehensive Cancer Network
        NCCN clinical practice guidelines in oncology: melanoma. NCCN.
        (Version 1.2019 — November 1) (Oct 12th, 2020)
        • Schuitevoerder D.
        • Grinlington L.
        • Stevens J.
        • et al.
        Nonvisualized sentinel lymph nodes on lymphoscintigraphy in melanoma: predictive factors and surgical outcomes.
        Nucl Med Commun. 2017; 38: 383-387
        • Social Science Statistics
        (Available at:) (June 15th, 2020)
        • Kaplan E.L.
        • Meier P.
        Nonparametric estimation from incomplete observations.
        J Am Stat Assoc. 1958; 53 (81): 457
        • Langley A.
        • Levesque L.
        • Baetz T.
        • et al.
        Brief report in melanoma incidence in ontario.
        J Cutan Med Surg. 2018; 22: 476-478
        • Pollack L.
        • Li J.
        • Berkowitz Z.
        • et al.
        Melanoma survival in the United States, 1992 to 2005.
        American Academy of Dermatology. 2011; 65: 78-86
        • Wangari-Talbot J.
        • Chen S.
        Genetics of melanoma.
        Front Genet. 2013; 3: 330
        • Curtin J.
        • Fridlyand J.
        • Kageshita T.
        • et al.
        Distinct sets of genetic alterations in melanoma.
        N Engl J Med. 2005; 53: 2135-2147
        • Fisher B.
        The evolution of paradigms for the management of breast cancer: a personal perspective.
        Canc Res. 1992; 52: 2371-2383
        • Vetto J.T.
        • Hsueh E.C.
        • Gastman B.R.
        • et al.
        Guidance of sentinel node biopsy decisions in patients with T1-2 melanoma using gene expression profiling.
        Future Oncol. 2019; 15: 1207-1217
        • Egger M.E.
        • Stevenson M.
        • Bhutiani N.
        • et al.
        Should sentinel lymph node biopsy be performed for all T1b melanomas in the new 8(th) Edition American Joint Committee on Cancer Staging System?.
        J Am Coll Surg. 2019; 228: 466-472